Trials / Terminated
TerminatedNCT00283842
Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, 13-Week, Adaptive-Design Study of 4 Fixed Oral Doses of DVS SR in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 408 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DVS SR | |
| DRUG | Placebo |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2006-01-30
- Last updated
- 2011-10-24
- Results posted
- 2009-08-13
Locations
51 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00283842. Inclusion in this directory is not an endorsement.